Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (9708)	9/10/2001 1:54:59 PM
From: Bucky Katt	Respond to of 13094

I have a list on that somewhere...One I do remember was BJCT from a rat of a little over a buck to $15, but that was a while ago, like 2 years or something.. When I find the list, I'll post it.

To: Sergio H who wrote (9708)	9/10/2001 6:46:12 PM
From: Jibacoa	Read Replies (1) \| Respond to of 13094

Sergio: On the "small cap" group that may derive some benefit from diabetic related treatment. IMHO the first two that come to mind are AMLN and SPEX (the old Biospherics.<g>) There are several others that have "an iron on the fire", but for most of them the "diabetic research or product" is a small factor or it is years away from coming to market. Here is a "list" (in alphabetical order) from some notes I had on that subject.<g> AMLN (The Company is developing Symlin (pramlintide acetate) for the treatment of diabetes patients who use insulin. Symlin is a synthetic analog of the human hormone amylin that was invented by the Company's scientists. The Company has completed clinical testing of Symlin that it believes is sufficient to support United States Food and Drug administration approval to market Symlin. The Company submitted a New Drug Application for Symlin to the FDA in December 2000, and this application was filed for review by the FDA in January 2001) (With Alkermes, it is trying to develop an injectable long-acting formulation of AC2993, that would allow once-a-month administration of AC2993 for the treatment of type II diabetes.) CRIS (Has small program for diabetes, which is still many years away.) CYGN (manufactures an automatic and non-invasive glucose monitoring device, the GlucoWatch) EMIS (The Company is in the process of developing an oral insulin formulation. It seems it will be 2 yrs. Before they start human trials) GENXY (Genset's researchers have isolated by differential expression a novel gene expressed in the liver of several hyperglycemic animal models. If of any value it is years away.) INHL (In collaboration with Pfizer for past 6 yrs., since January 1995, is developing an inhaled version of regular insulin.) IPIC (Has a pituitary adenylate cyclase activating polypeptide (PACAP) in early stages of development which among other uses may be helpful for diabetes.) LEXG (On April 17 announced that it had delivered to BMY the 2nd installment of its database These gene functions are being analyzed for pharmaceutical product potential in the areas of cancer, cardiovascular disease, immune disorders, neurological disease, DIABETES and obesity.) MLNM (In March 2001, the Company entered into a broad alliance with Abbott Laboratories that includes joint development and commercialization of drugs for the treatment and management of obesity and type II diabetes.) NBIX (Has an altered peptide ligand that affects immune cells targeting the pancreas. In preclinical studies, this altered peptide ligand, NBI-6024, was capable of reducing the incidence of diabetes. In addition, experiments using immune cells derived from the blood of Type 1 diabetes patients indicated that patients' immune cells recognize NBI-6024. This suggests that NBI-6024 may have the potential to intervene in the disease process in humans.) SPEX (Spherix has patented the use of tagatose as a treatment against Type II diabetes. Two small clinical trials at the University of Maryland School of Medicine have found tagatose effective as an adjuvant treatment for this form of diabetes.) STEM (Since 1998 when it obtained a license from The Scripps Research Institute. It has been working on the identification and isolation of pancreas stem and progenitor cells.) TELK (Has a family of small molecule product candidates that bind to the insulin receptor. These products, like insulin, cause the receptor to activate and initiate a sequence of events called insulin signaling, which lowers sugar levels in the blood by facilitating the entry of sugar into muscle and liver cells.) VLTS ( Has an experimental product: PEGylated oral insulin for Diabetes mellitus.) I don't know if that helps you. (And I don't know how complete that "list" is.<g>) RAGL Bernard